• Anteris raises $US 320 million through public offering and private placement
• Proceeds to support DurAVR® THV global pivotal trial and manufacturing expansion
• Medtronic plc invests $US 90 million through private placement

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a global structural heart company, has announced the closing of its underwritten public offering of 40,000,000 shares of common stock, including the exercise in full of the underwriters' option to purchase additional shares, at a public offering price of $US 5.75 per share. The company also announced the closing of its previously announced sale, in a private placement, of 15,652,173 shares of common stock to Medtronic plc (through a wholly owned subsidiary) at the same price per share. The gross proceeds to Anteris from the offering and the private placement were approximately $US 320 million, prior to deducting underwriting discounts, commissions, placement agent fees, and estimated expenses. Anteris intends to use the net proceeds to support the next stage of growth and advance the execution of the company's clinical strategy, including ongoing recruitment and study execution of the DurAVR® Transcatheter Heart Valve (DurAVR® THV) global pivotal trial for patients with severe aortic stenosis (the PARADIGM Trial) and expansion of manufacturing capabilities. A portion of the proceeds is also expected to fund ongoing research and development for v2vmedtech, inc., with the balance allocated to working capital and other general corporate purposes.

Anteris plans to use the net proceeds from the offering and private placement to support the next stage of growth and advance the execution of the company's clinical strategy, including the DurAVR® THV global pivotal trial and expansion of manufacturing capabilities.